Raha, Sohini
Eli Lilly (United States)
3 papers on CoChatORCID 0000-0002-8459-8534
Most cited papers
- Verified
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 478
- Verified
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 73
- Verified
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight
Ma, X., Li, Y. G., Raha, S., Sperry, D. C., Coutant, D. E., & Bhattachar, S. (2026) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free